Olema Oncology to Unveil Early OP-3136 Data at 2026 ASCO Meeting — Olema Pharmaceuticals, Inc.

Event summary

Olema Oncology will present initial Phase 1 clinical data for OP-3136 at the 2026 ASCO Annual Meeting on May 30.
The poster presentation (Abstract #3088) will cover OP-3136 as monotherapy and in combination with endocrine therapy in ER+, HER2- advanced breast cancer.
Olema will also present a trial-in-progress poster for the Phase 3 OPERA-02 trial on June 1.
OP-3136 is a novel oral selective KAT6A/B inhibitor, currently in Phase 1 clinical study.

The big picture

Olema Oncology's presentation at the 2026 ASCO Annual Meeting marks a critical milestone in the development of OP-3136, a novel KAT6A/B inhibitor targeting advanced breast cancer. The data could influence the competitive landscape for endocrine-driven cancer therapies, particularly as Olema seeks to differentiate its pipeline in a crowded oncology market. The strategic focus on combination therapies aligns with broader industry trends toward personalized and multi-targeted treatment approaches.

What we're watching

Clinical Efficacy: How the initial Phase 1 data for OP-3136 will position it against existing therapies in ER+, HER2- advanced breast cancer.
Regulatory Pathway: Whether the FDA Fast Track designation for palazestrant will accelerate OP-3136's development timeline.
Combination Therapy: The pace at which Olema can demonstrate synergistic effects of OP-3136 with endocrine therapies and CDK4/6 inhibitors.